Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2756268 | 1.00 | CYP3A4 (0.49) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12066913 | 0.90 | CYP3A4 (0.47) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16405091 | 0.90 | CYP3A4 (0.47) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL13071010 | 0.90 | CYP3A4 (0.47) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL239407 | 0.88 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12598148 | 0.88 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL239406 | 0.88 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL242197 | 0.88 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12566960 | 0.88 | DPP4 (0.51) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12567110 | 0.88 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885KCNH2 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.